Abstract 4340802: Right Ventricular Longitudinal Strain Indexed to Right Ventricular Systolic Pressure for Detecting Right Ventricular-Pulmonary Artery Uncoupling and Mortality in Pulmonary Hypertension Patients

M Mohammed Tiseer Abbas (Mayo Clinic Arizona, Phoenix, Arizona, United States) J Juan Farina (Mayo Clinic, Phoenix, Arizona, United States) A Ahmed K. Mahmoud (Mayo Clinic Arizona, Phoenix, Arizona, United States) R Rachel Wraith (Mayo Clinic Arizona, Phoenix, Arizona, United States) L Lisa Brown (Mayo Clinic Arizona, Phoenix, Arizona, United States) C Christy Baxter (Mayo Clinic Arizona, Phoenix, Arizona, United States) A Arshad Mohammed (Discovery Science, Altos Labs) M Milagros Pereyra (Mayo Clinic Arizona, Phoenix, Arizona, United States) I Isabel Scalia (Mayo Clinic Arizona, Phoenix, Arizona, United States) K Kamal Awad N Nima Baba (Mayo Clinic Arizona, Phoenix, Arizona, United States) S Sogol Attaripour Esfahani (Mayo Clinic, Phoenix, AZ, Phoenix, Arizona, United States) H Hesham Sheashaa (Mayo Clinic, Phoenix, AZ, Phoenix, Arizona, United States) N Nadera Bismee (Mayo Clinic Arizona, Phoenix, Arizona, United States) O Omar Ibrahim (Mayo Clinic, Phoenix, AZ, Phoenix, Arizona, United States) F Fatmaelzahraa Abdelfattah (Mayo Clinic Arizona, Phoenix, Arizona, United States) R Robert Scott T Timothy Barry C Chadi Ayoub (Mayo Clinic, Scottsdale, Arizona, United States) R Reza Arsanjani (Mayo Clinic, Scottsdale, Arizona, United States)

Abstract

Background: A key determinant of prognosis in pulmonary hypertension (PH) is the right ventricle’s (RV) ability to adapt to increased pulmonary vascular resistance. Consequently, markers of RV-pulmonary artery (PA) coupling may improve prognostic prediction in PH. The ratio of tricuspid annular plane systolic excursion (TAPSE) to systolic PA pressure (sPAP) has been proposed as a surrogate for RV-PA coupling and a reliable prognostic marker, however, the existing data on the prognostic value of the ratio between RV longitudinal strain (RVLS) and sPAP as a surrogate for RV-PA coupling is scarce. Hypothesis: To evaluate the prognostic role of RVLS/RVSP in PH patients and to compare this novel marker with established markers of RV-PA coupling. Methods: This is a single-center study that included adult patients with PH classified as group I or IV, all of whom had undergone a transthoracic echocardiogram (TTE) within one year prior to the initiation of PH-specific treatment. Certified sonographers procured RV strain measurements using a specific software (Epsilon Imaging, Ann Arbor, MI). Receiver operating characteristic (ROC) analysis was used to determine the best cutoff for predicting all-cause mortality at one-year for RVLS/RVSP and TAPSE/RVSP. The association of RVLS/RVSP and TAPSE/RVSP with mortality at one year was assessed using the Kaplan-Meier analysis and multivariate Cox regression analysis (adjusted for REVEAL LITE 2.0 risk score). Results: A total of 160 patients were included with a median age of 67.2 (56.8, 73.7) years and 47 (29.2%) were male . ROC analysis revealed optimal cutoffs of 0.265 (AUC = 0.83) for RVLS/RVSP and 0.185 (AUC = 0.77) for TAPSE/RVSP to predict all-cause mortality at one year. One-year cumulative incidence of all-cause mortality was lower among patients with RVLS/RVSP ≥ 0.265 (0 % vs 13.7 %, p = 0.001) and patients with TAPSE/RVSP ≥ 0.185 (1.8 % vs 16.7 %, p = 0.001) (Figure 1) . In the multivariate analysis, RVLS/RVSP < 0.265 was associated with higher risk of mortality at one year (HR: 2.38, 95 % CI: 1.05 to 5.38, p = 0.036) while TAPSE/RVSP < 0.185 was not (HR: 2.01, 95 % CI: 0.93 to 4.31, p = 0.072). Conclusions: RVLS/ RVSP may be a valuable prognostic marker in PH patients and could outperform conventional TTE parameters as a surrogate for detecting RV-PA coupling.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (20)

M

Mohammed Tiseer Abbas

Mayo Clinic Arizona, Phoenix, Arizona, United States

J

Juan Farina

Mayo Clinic, Phoenix, Arizona, United States

A

Ahmed K. Mahmoud

Mayo Clinic Arizona, Phoenix, Arizona, United States

R

Rachel Wraith

Mayo Clinic Arizona, Phoenix, Arizona, United States

L

Lisa Brown

Mayo Clinic Arizona, Phoenix, Arizona, United States

C

Christy Baxter

Mayo Clinic Arizona, Phoenix, Arizona, United States

A

Arshad Mohammed

Discovery Science, Altos Labs

M

Milagros Pereyra

Mayo Clinic Arizona, Phoenix, Arizona, United States

I

Isabel Scalia

Mayo Clinic Arizona, Phoenix, Arizona, United States

K

Kamal Awad

N

Nima Baba

Mayo Clinic Arizona, Phoenix, Arizona, United States

S

Sogol Attaripour Esfahani

Mayo Clinic, Phoenix, AZ, Phoenix, Arizona, United States

H

Hesham Sheashaa

Mayo Clinic, Phoenix, AZ, Phoenix, Arizona, United States

N

Nadera Bismee

Mayo Clinic Arizona, Phoenix, Arizona, United States

O

Omar Ibrahim

Mayo Clinic, Phoenix, AZ, Phoenix, Arizona, United States

F

Fatmaelzahraa Abdelfattah

Mayo Clinic Arizona, Phoenix, Arizona, United States

R

Robert Scott

T

Timothy Barry

C

Chadi Ayoub

Mayo Clinic, Scottsdale, Arizona, United States

R

Reza Arsanjani

Mayo Clinic, Scottsdale, Arizona, United States